NCT07494019 · NYU Langone Health
Community Safety and Violence
What this study is about
This study will describe, estimate, and explore the effectiveness of community-centered safety models (CCSMs)-including co-response, alternative response, and community violence intervention modalities-implemented across U.S. municipalities to prevent community violence among youth and young adults (YYA).
View original scientific description
This study will describe, estimate, and explore the effectiveness of community-centered safety models (CCSMs)-including co-response, alternative response, and community violence intervention modalities-implemented across U.S. municipalities to prevent community violence among youth and young adults (YYA). Specifically, the investigators will (1) describe CCSM implementation using implementation-science methods, (2) estimate CCSMs' impacts on community-violence outcomes using quasi-experimental methods, and (3) explore operational and contextual factors associated with stronger or weaker effects.
Primary outcome measures
Homicide Rate
Time frame: Baseline, Month 36
Measured as deaths per 100,000 (annual).
Firearm Homicide Rate
Time frame: Baseline, Month 36
Measured as deaths per 100,000 (annual).
Assault-related ED & inpatient encounters (combined) rate
Time frame: Baseline, Month 36
Measured as visits/admissions per 10,000 (monthly).
Firearm-assault-related ED & inpatient encounters (combined) rate
Time frame: Baseline, Month 36
Measured as hospitalizations per 10,000 (monthly).
Nonfatal firearm assault rate
Time frame: Baseline, Month 36
Measured as hospitalizations per 10,000 (monthly).
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- for Jurisdiction/Sites:
- Intervention modality clarity: A single, identifiable CCSM-Co-Response (CRM), Alternative Response (ARM), or Community Violence Intervention (CVI)-implemented at city/county level.
- Documented launch date \& scope: Public or official documentation specifying program start date, catchment, operating hours, staffing, eligibility, and core activities.
- Observation window: ≥24 months pre-implementation and ≥12 months post-implementation of outcome data (monthly preferred; annual acceptable for fatal outcomes).
- Outcomes coverage: Availability of primary outcomes (fatal and nonfatal violent injury) and at least one secondary justice outcome at the jurisdiction level.
- Data quality: Stable geographic boundaries, consistent reporting practices, and no catastrophic breaks that preclude credible counterfactual fit.
- Donor comparability: Jurisdiction characteristics and data cadence compatible with a pooled augmented synthetic control design (i.e., can be matched to a synthetic control and included in permutation tests).
Exclusion criteria
- Pilot-only or indeterminate programs: Short-lived pilots, ambiguous or multi-modality rollouts where treatment timing or content cannot be reliably defined.
- Severe data discontinuity: Major boundary changes, reporting suspensions, coding overhauls, or dataset gaps that undermine time-series integrity (e.g., prolonged outages during system migration) and cannot be addressed with standard remedies.
- Overlapping major interventions: Concurrent, poorly measured citywide initiatives (e.g., sweeping policy bundles) that coincide with the CCSM start and make identification infeasible.
- Insufficient pre-period: \<24 months pre-implementation data for primary outcomes.
- Incompatible cadence/aggregation: Outcomes only available at spatial or temporal units that cannot be aligned with other sites or donors.
Where
- New York, New York
Collaborators
Centers for Disease Control and Prevention
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Mar 27, 2026 · Source of record for eligibility and locations